Background: Sphincter-preserving procedures for the treatment of transsphincteric fistulas fail in at least one out of every three patients. It has been suggested that failure is due to ongoing disease in the remaining fistula tract. Cytokines play an important role in inflammation. At present, biologicals targeting cytokines are available. Therefore, detection and identification of cytokines in anal fistulas might have implications for future treatment modalities. The objective of the present study was to assess local production of a selected panel of cytokines in anal fistulas, including pro-inflammatory interleukin (IL)-1β and tumor necrosis factor α (TNF-α). Methods: Fistula tract tissue was obtained from 27 patients with a transsphinct...
The cryptoglandular hypothesis as an explanation for the aetiology, pathogenesis and maintenance of ...
Background: Fistulas represent a frequent and severe complication in patients with Crohn disease (CD...
INTRODUCTION: Infliximab is a monoclonal antibody against tumor necrosis factor-alpha, which has bee...
Sphincter-preserving procedures for the treatment of transsphincteric fistulas fail in at least one ...
Aim: The pathogenesis of cryptoglandular anal fistula (AF) is still under debate. Tissue inflammatio...
Aim: The aetiology of cryptoglandular anal fistula (AF) is poorly understood. Evidence suggests that...
The factors leading to the creation and persistence of anal fistula in Crohn’s disease are poorly un...
Cryptoglandular perianal fistula is a common benign anorectal disorder that is managed mainly with s...
PURPOSE: This study was designed to assess the healing rate of complex perianal fistulas in Crohn's ...
Antitumor necrosis factor alpha (anti-TNF-alpha) therapy in perianal Crohn's disease (CD) is widely ...
Abstract BACKGROUND: Nowadays anti-TNF-alpha antibodies are used for the treatment of perianal Croh...
Objectives: Anti-TNF agents are effective to treat perianal Crohn’s disease (CD). Evidence suggests ...
�� 2011 The Authors. Published by BMC, part of Springer Nature. This is an open access article avail...
Background: Tumour necrosis factor alpha (TNF-α) is a cytokine elevated in inflammatory bowel diseas...
Anal fistulas occurring in Crohn’s disease (CD) comprise a risk factor of severe course of inflammat...
The cryptoglandular hypothesis as an explanation for the aetiology, pathogenesis and maintenance of ...
Background: Fistulas represent a frequent and severe complication in patients with Crohn disease (CD...
INTRODUCTION: Infliximab is a monoclonal antibody against tumor necrosis factor-alpha, which has bee...
Sphincter-preserving procedures for the treatment of transsphincteric fistulas fail in at least one ...
Aim: The pathogenesis of cryptoglandular anal fistula (AF) is still under debate. Tissue inflammatio...
Aim: The aetiology of cryptoglandular anal fistula (AF) is poorly understood. Evidence suggests that...
The factors leading to the creation and persistence of anal fistula in Crohn’s disease are poorly un...
Cryptoglandular perianal fistula is a common benign anorectal disorder that is managed mainly with s...
PURPOSE: This study was designed to assess the healing rate of complex perianal fistulas in Crohn's ...
Antitumor necrosis factor alpha (anti-TNF-alpha) therapy in perianal Crohn's disease (CD) is widely ...
Abstract BACKGROUND: Nowadays anti-TNF-alpha antibodies are used for the treatment of perianal Croh...
Objectives: Anti-TNF agents are effective to treat perianal Crohn’s disease (CD). Evidence suggests ...
�� 2011 The Authors. Published by BMC, part of Springer Nature. This is an open access article avail...
Background: Tumour necrosis factor alpha (TNF-α) is a cytokine elevated in inflammatory bowel diseas...
Anal fistulas occurring in Crohn’s disease (CD) comprise a risk factor of severe course of inflammat...
The cryptoglandular hypothesis as an explanation for the aetiology, pathogenesis and maintenance of ...
Background: Fistulas represent a frequent and severe complication in patients with Crohn disease (CD...
INTRODUCTION: Infliximab is a monoclonal antibody against tumor necrosis factor-alpha, which has bee...